The Clinical Advances in Stem Cell Research program will explore current cellular therapies in the clinic and those moving toward it as well as emerging technologies and their potential impact on clinical practice. Held the day before the ISSCR Annual Meeting, this program is designed for physicians, physician-scientists and those interested in the latest clinical applications of stem cell research.
Additional registration and fee required
Location Offsite: Walter and Eliza Hall Institute of Medical Research (WEHI)

Pre-Meeting Education: Clinical Advances in Stem Cell Research

09:15 - 17:30


Miles Prince

Professor Miles Prince AM is an Australian haematologist and Professor of Medicine at both Melbourne and Monash Universities. He is the Professor/Director of Cancer Immunology and Molecular Oncology at Epworth Healthcare and also Director of the Centre for Blood Cell Therapies at the Peter MacCallum Cancer Centre.

He is the Chairman of Medical Scientific Advisory Group to Myeloma Australia and Lead of the Australian T cell Lymphoma Network. He is on the Steering Committees of the LymphomaHub and MultiplemyelomaHub.

He is a very active clinician, also overseeing clinical and laboratory research – the latter involving stem cell research and cancer immunology. He has been involved in numerous clinical trials of new therapies for blood cancers and has been the Principal Investigator of over 100 clinical trials involving myeloma, lymphoma, leukaemia, transplantation and supportive care.

He has published over 400 peer-reviewed manuscripts. He is the Chief Investigator for an NH&MRC Program Grant in Cancer Immunology, Victorian Cancer Agency translational grants in Epigenetics, Melbourne Genomics Health Alliance and holds large US and European research grants.

He is one of the founding Directors of the Snowdome Foundation which focuses on ‘accelerating new therapies for Australian patients with blood cancers’.

He is a Fellow of the Academy of Health & Medical Sciences and in 2014 Miles was appointed a Member of the Order of Australia for distinguished services to medicine particularly in the areas of blood cancer research, patient care and philanthropy leadership.


Send Email for Miles Prince

Francoise Mechinaud


Send Email for Francoise Mechinaud

Bob Valamehr

Fate Therapeutics, Inc, United States

Bob Valamehr is the Vice President of Cancer Immunotherapy at Fate Therapeutics, overseeing the company’s immuno-oncology and pluripotent stem cell programs, including efforts to develop novel pluripotent cell strategies to create “off-the-shelf” cell-based cancer immunotherapeutics. Previously, Dr. Valamehr has played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA and his M.B.A. from Pepperdine University.


Send Email for Bob Valamehr

Seigo Izumo

Dr. Seigo Izumo is Senior Vice President, Global Head of Regenerative Medicine Unit and Head of Scientific Affairs in Japan at Takeda Pharmaceutical Company. Previously he served as Senior VP & Head of Cardiovascular Therapeutics at Gilead Sciences, and VP & Global Head of Cardiovascular Research at Novartis. Prior to joining the industry, Dr. Izumo was Professor of Medicine, Harvard Medical School and Director of Cardiovascular Research, Beth Israel Deaconess Medical Center, Boston, and Chief of Cardiology Division, Professor of Internal Medicine & Biological Chemistry and Director of the Center for Organogenesis, University of Michigan Medical School. Dr. Izumo graduated from University of Tokyo and received clinical and research trainings at Harvard-affiliated Beth Israel Hospital and The Children's Hospital, Boston. He is a board-certified physician in internal medicine and cardiovascular disease.


Send Email for Seigo Izumo

Graziella Pellegrini

University of Modena and Reggio Emilia, Italy

ISSCR Innovation Award co-recipient

Graziella Pellegrini is Full Professor of Biology, University of Modena and Reggio Emilia. She is Coordinator of the Cell Therapy and Qualified Person of Center for Regenerative Medicine, R&D Director and co-founder of Holostem Terapie Avanzate. She has relevant experience on epithelial stem cells, melanocytes for pigmentation disorders, oral mucosa, urethra, phase I gene therapy of epidermolysis bullosa, cell therapy by cultured human epidermis, of ocular surface from 1995, for treatment of limbal stem cell deficiency blindness; translation of cell therapy under ATMP European rules.


Send Email for Graziella Pellegrini

Jeremy Sugarman

Johns Hopkins University, United States

Jeremy Sugarman, MD, MPH, MA is the Harvey M. Meyerhoff Professor of Bioethics & Medicine, professor of medicine, professor of Health Policy and Management, and deputy director for medicine of the Berman Institute of Bioethics at Johns Hopkins University. He is internationally recognized as a leader in biomedical ethics with particular expertise in applying empirical methods and evidence-based standards for evaluating and analyzing bioethical issues. His contributions to both bioethics and policy include his work on the ethics of informed consent, umbilical cord blood banking, stem cell research, international HIV prevention research, global health, and research oversight. He has served on the Maryland Stem Cell Research Commission and is a member of ISSCR’s Ethics and Public Policy Committees. He also co-chairs the Johns Hopkins’ Institutional Stem Cell Research Oversight Committee. Dr. Sugarman has been elected as a member of the American Society of Clinical Investigation, Association of American Physicians, and the Institute of Medicine. He is a fellow of the American Association for the Advancement of Science, the American College of Physicians and the Hastings Center.


Send Email for Jeremy Sugarman

Tracy C. Grikscheit

The Saban Research Institute at Children's Hospital Los Angeles, CA, United States

Tracy Grikscheit, MD, FACS, FAAP is a tenured Associate Professor of Surgery at the University of Southern California, as well as an Attending Pediatric Surgeon at Children’s Hospital Los Angeles. Dr. Grikscheit is funded primary investigator at the Saban Research Institute, Her research interests include tissue engineering, the role of organ-specific and iPS stem cells in organ regeneration and replacement.


Send Email for Tracy Grikscheit

Trevor Kilpatrick

Trevor Kilpatrick is a Professor of Neurology and Director of the Melbourne Neuroscience Institute at The University of Melbourne; he is the leader of the MS Division at the Florey Institute of Neuroscience and Mental Health and is a neurologist and Head of the MS Unit at the Royal Melbourne Hospital.

Professor Kilpatrick graduated with a Bachelor of Medicine, Bachelor of Surgery from the University of Melbourne in 1982 and then went on to specialise in neurology. He undertook graduate studies at The University of Melbourne and gained a Doctor of Philosophy in 1993. Appointments at The Salk Institute for Biological Studies (La Jolla, USA), Institute of Neurology (London, UK) and The National Hospital and Moorfields Eye Hospital (London, UK) followed. He returned to Melbourne as the Viertel Senior Medical Research Fellow at the Walter & Eliza Hall Institute for Medical Research and as the Head of the Melbourne Multiple Sclerosis Research Unit at the Royal Melbourne Hospital.

Professor Kilpatrick has been the recipient of the Sunderland Award (1994), AMRAD Postdoctoral Award (1995), inaugural Leonard Cox Award (2000), Bethlehem Griffiths Research Foundation Award for Medical Research (2004), the Australian Museum’s Jamie Callachor Eureka Prize for Medical Research (2008), the Stephen C. Reingold Research Award by the US MS National Multiple Sclerosis Society (2010) and most recently, (2013), Professor Kilpatrick was awarded the Bethlehem Griffiths Research Foundation Medal for outstanding leadership in medical research.

Professor Kilpatrick has published widely including publications in Nature, Nature Genetics and Nature Medicine. His research interests include the neurobiology of multiple sclerosis, neural precursor cell biology and the study of genetic and environmental factors that contribute to MS as well as the translation of basic research discoveries to the clinic.


Send Email for Trevor Kilpatrick

Sarah Busch

Sarah Busch, PhD brings deep expertise in cell therapies for CNS disease and injury to her position as Associate Director of Neuroscience at Athersys, Inc. Since 2010, she has focused on advancing the MultiStem® cell therapy platform through preclinical development in ischemic stroke, spinal cord injury, multiple sclerosis, and traumatic brain injury among others. Dr. Busch is proficient in the development pathways for cellular therapeutics, including models for validation and improvement of the cell product, cell-based potency assays, animal models and clinical trial design. Dr. Busch has authored several peer reviewed manuscripts on spinal cord injury with a focus on the interaction between neural and immune cells. Further, she is the inventor on several patents involving the use of stem cells for treating disease. Dr. Busch contributed to realization of grant funding from the Ohio Third Frontier, and received a Small Business Initiated Research Grant through the National Institute of Neurological Disease and Stroke. Most recently, she was awarded a Department of Defense grant encompassing the regulatory and planning steps necessary to submit an Investigational New Drug application to the United States FDA for the use of MultiStem® in a Phase II clinical trial for treating patients suffering from acute spinal cord injuries. Dr. Busch received her PhD in 2009 from Case Western Reserve University in the laboratory of Dr. Jerry Silver. She is an active member of the National Center for Regenerative Medicine, the Society for Neuroscience, the Spinal Cord Outcomes Partnership Endeavor.


Send Email for Sarah Busch

Kathleen Reape

Kathy Reape is Head of Clinical R&D at Spark Therapeutics. She received her MD from the University of Pennsylvania and completed her internship and residency at the University of Florida and the University of Medicine and Dentistry of New Jersey. She has more than 18 years of pharmaceutical industry experience in clinical drug development at Wyeth, Teva and Allergan, prior to joining Spark. She has been involved with numerous clinical trials as well as the approvals of more than 2 dozen products including small molecules, biologics, biosimilars, and devices, spanning a wide range of therapeutic areas.


Send Email for Kathleen Reape

Roger Barker

University of Cambridge

Roger Barker is the Professor of Clinical Neuroscience at the University of Cambridge and Consultant Neurologist at the Addenbrooke's Hospital Cambridge. He is a guest professor at the University of Lund, Sweden and a PI in the MRC-Wellcome Trust Stem Cell Institute in Cambridge. For the last 25 years he has run research that seeks to better define the clinical heterogeneity of two common neurodegenerative disorders of the CNS- namely Parkinson's (PD) and Huntington's disease (HD). This has helped him define the best way by which to take new treatments into the clinic, in particular cell based therapies. He currently co-ordinates an EU funded transplant programme using human fetal tissue for patients with PD and is part of a new EU and global initiative (GFORCE-PD) that is seeking to take stem cells to trial in patients with PD.


Send Email for Roger Barker


Pre-Meeting Education: Clinical Advances in Stem Cell Research

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Pre-Meeting Education: Clinical Advances in Stem Cell Research